LABP Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own LABP shares is 18, representing 52.04% of the company's common stock.

GEODE CAPITAL MANAGEMENT, LLC, in the last quarter, reduced its stake in LABP by -0.76% restricting it's holding to 91.54 thousand shares of worth nearly $27.28K. RENAISSANCE TECHNOLOGIES LLC also lessened -36.84% of the LABP shares from its portfolio, reducing its holding to 79.2 thousand shares of worth $24.00K. BRIDGEWAY CAPITAL MANAGEMENT, LLC also shunned LABP shares holding by -60.61% last quarter which brought its holding to 39 thousand shares worth $11.62K.

As per its latest 13F filing, CORNERSTONE PLANNING GROUP LLC increased its stake in LABP by 100% in the last quarter. The institutional holder raised its holding to 12 shares having worth more than $44.00. CITADEL ADVISORS LLC also added 100% more shares of LABP to its portfolio, raising its holding to 86.09 thousand shares of worth $25.66K. WARBERG ASSET MANAGEMENT LLC also increased its LABP shares holding by 100% which brought its holding to 73.5 thousand shares worth $21.90M.

The insider with the most stakes in LABP is Poukalov Konstantin , at the company. Additionally, LABP stock is highly held by 10 percent owner RTW INVESTMENTS, LP and director PERCEPTIVE ADVISORS LLC among others.

Company executives, directors, and other insiders own 9.89% percent of Landos Biopharma, Inc.'s stock. Within the last six months, there have been 0 transaction(s) in which LABP insiders have sold stock, totaling 0 shares. Insiders that have sold shares include BASSAGANYA-RIERA JOSEP and RTW INVESTMENTS, LP.

There have been 0 transaction(s) during the past 6-months in which Landos Biopharma, Inc. insiders have bought stock, totalling 0 shares

Around 0 Landos Biopharma, Inc. shares are held by insiders, which represents about 9.89% of LABP stock.

LABP , Poukalov Konstantin holds the largest portfolio of the company's shares. LABP shares owned by Poukalov total nearly 14.83 million.

CORNERSTONE PLANNING GROUP LLC is the largest institutional owner in LABP which holds 12 shares worth $267.00 or 0% of the total LABP shares outstanding followed by CORNERSTONE PLANNING GROUP LLC with ownership of 12 shares representing 0% of the LABP ownership. MACQUARIE GROUP LTD is the third largest stakeholder with 147.18 thousand shares or 0.02% of the ownership worth more than $44.00K.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the LABP is concerned, it is a stock which is not optionable.

Number of LABP shares short is 1.43K. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 3.13M shares of LABP are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, LABP has 1.33M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for LABP is 0.08.